Results 1 to 10 of about 209,213 (308)

Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study [PDF]

BMC Pulmonary Medicine
Background Asbestosis and idiopathic pulmonary fibrosis (IPF) share overlapping clinical and pathological features; however, differences in comorbidities and prognostic patterns between the two diseases remain poorly defined.
Yawen Song, Yuanying Wang, Nafeisa Dilixiati, Dongmei Wang, Yiran Wang, Qiao Ye   +5 more
doaj   +2 more sources

Analysis of body composition with bioelectrical impedance analysis in different subtypes of pulmonary fibrosis [PDF]

Scientific Reports
Patients with Idiopathic Pulmonary Fibrosis (IPF) often have an unfavourable body composition, characterized by a reduced phase angle (PhA) as an index of cellular health and associated with increased mortality.
Katharina Buschulte, Ben Ehrhart, Bernhard Kötter, Katharina Abbasi Dezfouli, Oliver Weinheimer, Katharina Cremer, Christoph Lederer, Philipp Höger, Markus Polke, Felix F. J. Herth, Judith Brock   +10 more
doaj   +2 more sources

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis

Respiratory Research, 2022
Background Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis.
M. C. Schimmelpennink, D. B. Meek, A. D. M. Vorselaars, L. C. M. Langezaal, C. H. M. van Moorsel, J. J. van der Vis, M. Veltkamp, J. C. Grutters   +7 more
doaj   +1 more source

Heterogeneity of mononuclear phagocytes in interstitial lung diseases [PDF]

, 1990
Interstitial lung diseases are a heterogeneous group of illnesses with different pathogeneses. In interstitial lung diseases there often is an increased influx of cells from the peripheral blood (PB) to the interstitium and alveoli.
Hoogsteden, H.C. (Henk)
core   +16 more sources

Clustering of lung diseases in the family of interstitial lung disease patients

BMC Pulmonary Medicine, 2022
Background The presence of familial interstitial lung disease (ILD) has been found to predict development of progressive pulmonary fibrosis. However, the role of non-ILD lung diseases in ILD patients’ families has not yet been investigated.
Michelle Terwiel, Jan C. Grutters, Coline H. M. van Moorsel   +2 more
doaj   +1 more source

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis

Medicina, 2023
Background and Objectives: Progressive pulmonary fibrosis (PPF) is a recently described term reserved for patients with fibrotic ILD other than idiopathic pulmonary fibrosis (IPF) with fast clinical deterioration. Here, survival and prognostic biomarkers
Mark G. J. P. Platenburg, Joanne J. van der Vis, Jan C. Grutters, Coline H. M. van Moorsel   +3 more
doaj   +1 more source

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis

ERJ Open Research, 2023
Background Telomere dysfunction can underly the development of idiopathic pulmonary fibrosis (IPF), and recent work suggests that patients with telomere syndromes might benefit from treatment with androgens, such as danazol.
Thijs W. Hoffman, Coline H.M. van Moorsel, Joanne J. van der Vis, Douwe H. Biesma, Jan C. Grutters   +4 more
doaj   +1 more source

Distinct metabolic features in the plasma of patients with silicosis and dust-exposed workers in China: a case–control study

BMC Pulmonary Medicine, 2021
Background Silicosis is a progressive pneumoconiosis characterized by interstitial fibrosis following exposure to silica dust. The role of metabolic dysregulation in the pathogenesis of silicosis has not been investigated in detail.
Changjiang Xue, Na Wu, Yali Fan, Jing Ma, Qiao Ye   +4 more
doaj   +1 more source

Cluster features in fibrosing interstitial lung disease and associations with prognosis

BMC Pulmonary Medicine, 2023
Background Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management.
Yuanying Wang, Di Sun, Jingwei Wang, Shiwen Yu, Na Wu, Qiao Ye   +5 more
doaj   +1 more source

Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype

Cells, 2021
Elevated Serum Amyloid A (SAA) levels have been found in several inflammatory diseases, including sarcoidosis. SAA is suggested to be involved in sarcoidosis pathogenesis by involvement in granuloma formation and maintenance.
Els Beijer, Claudia Roodenburg-Benschop, Milou C. Schimmelpennink, Jan C. Grutters, Bob Meek, Marcel Veltkamp   +5 more
doaj   +1 more source